HUTCHMED (China) Limited announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanc...
Roche announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab), presented at the 19th Asia-Pacific Vitreo-retina Soci...
Quoin Pharmaceuticals Ltd. (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and...
Roche announced that it has received FDA approval for expanded use of its PATHWAY® HER2 (4B5) and VENTANA® HER2 Dual ISH DNA Probe Coc...
Immuneering Corporation, a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, shared comments followi...
OmicsBank, a clinical data infrastructure company connecting fragmented hospital data for drug development and healthcare AI, announced $2.25 million in ...
Caliway Biopharmaceuticals, a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics, announced two major clinical mi...
Eisai Co., Ltd. and Biogen Inc., announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in th...
Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, announced that t...
Lexicon Pharmaceuticals, Inc. announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achiev...
SciSparc Ltd.(“Company” or “SciSparc”), announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...
Lakefront Biotherapeutics NV announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the ...
Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” announced that Opamtistomig (LBL-024), the Company&rsquo...
Ipsen announced it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navt...
© 2026 Biopharma Boardroom. All Rights Reserved.
